X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Book Chapter (281) 281
Journal Article (71) 71
Newspaper Article (8) 8
Patent (4) 4
Book Review (1) 1
Conference Proceeding (1) 1
Magazine Article (1) 1
Web Resource (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
life sciences & biomedicine (28) 28
science & technology (28) 28
humans (27) 27
female (15) 15
male (15) 15
middle aged (15) 15
rivaroxaban (15) 15
abridged index medicus (14) 14
cardiovascular system & cardiology (14) 14
peripheral vascular disease (11) 11
aged (10) 10
hematology (10) 10
adult (9) 9
anticoagulants (9) 9
anticoagulants - therapeutic use (8) 8
cardiac & cardiovascular systems (8) 8
double-blind method (8) 8
general & internal medicine (8) 8
venous thromboembolism (8) 8
enoxaparin - therapeutic use (7) 7
medicine, general & internal (7) 7
thrombosis (7) 7
aged, 80 and over (6) 6
anticoagulants - administration & dosage (6) 6
heparin (6) 6
risk factors (6) 6
thromboembolism (6) 6
anticoagulants - adverse effects (5) 5
drug therapy (5) 5
factor xa inhibitors (5) 5
venous thromboembolism - prevention & control (5) 5
administration, oral (4) 4
anticoagulants - pharmacology (4) 4
enoxaparin (4) 4
enoxaparin - administration & dosage (4) 4
follow-up studies (4) 4
heart failure (4) 4
hemorrhage - chemically induced (4) 4
morpholines - therapeutic use (4) 4
surgery (4) 4
thiophenes - therapeutic use (4) 4
time factors (4) 4
acute disease (3) 3
analysis (3) 3
anticoagulants - blood (3) 3
bone marrow - pathology (3) 3
calibration (3) 3
cardiac arrhythmia (3) 3
cardiovascular diseases (3) 3
care and treatment (3) 3
clinical trials (3) 3
colony-forming units assay (3) 3
dosage and administration (3) 3
dose-response relationship, drug (3) 3
drug administration schedule (3) 3
drug monitoring - methods (3) 3
embolisms (3) 3
enoxaparin - adverse effects (3) 3
factor xa inhibitors - adverse effects (3) 3
factor xa inhibitors - therapeutic use (3) 3
health aspects (3) 3
heparin - therapeutic use (3) 3
human necessities (3) 3
hygiene (3) 3
incidence (3) 3
medical or veterinary science (3) 3
morpholines - administration & dosage (3) 3
morpholines - adverse effects (3) 3
morpholines - blood (3) 3
morpholines - pharmacology (3) 3
mortality (3) 3
orthopedics (3) 3
patients (3) 3
plasma (3) 3
postoperative complications - prevention & control (3) 3
preparations for medical, dental, or toilet purposes (3) 3
pulmonary embolism (3) 3
rivaroxaban - therapeutic use (3) 3
specific therapeutic activity of chemical compounds ormedicinal preparations (3) 3
stroke (3) 3
thiophenes - administration & dosage (3) 3
thiophenes - adverse effects (3) 3
thiophenes - blood (3) 3
thiophenes - pharmacology (3) 3
aspirin (2) 2
bleeding (2) 2
bone marrow - drug effects (2) 2
cardiology and cardiovascular medicine (2) 2
cardiovascular disease (2) 2
citizenship (2) 2
coronary vessels (2) 2
deep-vein thrombosis (2) 2
drug monitoring (2) 2
drug therapy, combination (2) 2
efficacy (2) 2
europe (2) 2
evaluation (2) 2
exposure–response (2) 2
factor xa (2) 2
factor xa inhibitors - administration & dosage (2) 2
more...
Library Location Library Location
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Thrombosis and Haemostasis, ISSN 0340-6245, 02/2012, Volume 107, Issue 2, pp. 379 - 387
Journal Article
The New England journal of medicine, ISSN 1533-4406, 02/2013, Volume 368, Issue 6, pp. 513 - 523
Journal Article
The New England journal of medicine, ISSN 1533-4406, 10/2018, Volume 379, Issue 14, pp. 1332 - 1342
Patients with heart failure, coronary artery disease, and no atrial fibrillation were randomly assigned to receive 2.5 mg of rivaroxaban twice daily or... 
MORTALITY | THERAPY | EFFICACY | WARFARIN | THROMBIN | RANDOMIZED-TRIAL | ASPIRIN | FACTOR XA INHIBITOR | Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Myocardial Infarction - epidemiology | Follow-Up Studies | Humans | Middle Aged | Heart Failure - physiopathology | Male | Rivaroxaban - adverse effects | Treatment Failure | Female | Stroke - epidemiology | Drug Therapy, Combination | Platelet Aggregation Inhibitors - therapeutic use | Natriuretic Peptide, Brain - blood | Rivaroxaban - therapeutic use | Heart Failure - mortality | Heart Failure - complications | Stroke - prevention & control | Double-Blind Method | Kaplan-Meier Estimate | Coronary Artery Disease - drug therapy | Heart Failure - drug therapy | Stroke Volume | Factor Xa Inhibitors - therapeutic use | Coronary Artery Disease - complications | Factor Xa Inhibitors - adverse effects | Aged | Myocardial Infarction - prevention & control | Patient Readmission - statistics & numerical data | Heart failure | Rivaroxaban | Care and treatment | Dosage and administration | Safety and security measures | Coronary heart disease | Myocardial infarction | Performance evaluation | Cerebral infarction | Cardiac arrhythmia | Stroke | Heart attacks | Statistical analysis | Research & development--R&D | Embolisms | Coronary artery | Thrombin | Cardiovascular disease | Thrombosis | Patients | Coronary artery disease | Bleeding | Fibrillation | Coronary vessels | Ventricle | Heart diseases | Index Medicus | Abridged Index Medicus
Journal Article
Thrombosis journal, ISSN 1477-9560, 07/2013, Volume 11, Issue 1, pp. 11 - 11
...Author(s): Meyer Michel Samama[sup.1,2], Genevieve Contant[sup.3], Theodore E Spiro[sup.4], Elisabeth Perzborn[sup.5], Lena Le Flem[sup.2], Cnline Guinet[sup.2... 
Laboratory assessment | Rivaroxaban | Factor Xa | Thromboembolism | Pharmacokinetics | Risk factors | Anticoagulants | Cardiac arrhythmia | Plasma | Heart attacks | Laboratories | Embolisms | Clinical medicine | Drug therapy | Acute coronary syndromes | Joint replacement surgery | Thrombosis | Pharmaceuticals
Journal Article
Annals of Internal Medicine, ISSN 0003-4819, 02/2001, Volume 134, Issue 3, pp. 191 - I34
Journal Article
Thrombosis and Haemostasis, ISSN 0340-6245, 2016, Volume 115, Issue 6, pp. 1240 - 1248
Summary Hospital-associated venous thromboembolism (VTE) is a leading cause of premature death and disability worldwide. Evidence-based guidelines recommend... 
Trial Protocol Design Paper | Pulmonary embolism | Anticoagulants | Rivaroxaban | Deep-vein thrombosis | Medical patients | Thromboprophylaxis | Venous thromboembolism
Journal Article
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 05/2013, Volume 368, Issue 20, pp. 1944 - 1946
Journal Article
The New England journal of medicine, ISSN 0028-4793, 05/2013, Volume 368, Issue 20, pp. 1945 - 1946
Journal Article
Circulation (New York, N.Y.), ISSN 0009-7322, 11/2019, Volume 140, Issue Suppl_1 Suppl 1, pp. A12863 - A12863
IntroductionThromboprophylaxis extended after hospital discharge in high- risk medical patients remains controversial due to uncertainty about the benefit for... 
Rivaroxaban | Mortality | Analysis | Patient outcomes | Thromboembolism | Epidemiology | New Jersey
Journal Article